Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 7:09 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,710 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Muscle Disorders Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Muscle Function After Ankle Surgery

NCT00060970
View directory record Official record
Conditions
Muscle Atrophy, Muscle Weakness, Fractures
Interventions
Physical Therapy
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 7:09 PM EST
Completed No phase listed Observational

Critical Care Observation of Motor Activity (COMA) and SICU Outcomes

NCT02994641
View directory record Official record
Conditions
Motor Activity, Muscle Strength, Muscle Weakness
Interventions
COMA Score Assessment
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 112 Years
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Nov 2, 2026, 7:09 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Strain-Counterstrain Treatment of Piriformis Pain

NCT05023005
View directory record Official record
Conditions
Low Back Pain, Mechanical, Piriformis Syndrome, Somatic Dysfunction of Sacral Region (Finding)
Interventions
Strain-Counterstrain treatment of piriformis muscle
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 2 Interventional Results available

Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy

NCT00227266
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Valproic Acid and Levocarnitine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Nov 2, 2026, 7:09 PM EST
Completed Not applicable Interventional Results available

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

NCT01521546
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
eplerenone, placebo
Drug
Lead sponsor
Subha Raman
Other
Eligibility
7 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Nov 2, 2026, 7:09 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

A Multiple Component Mobile-aid Pain Reduction Intervention to Decrease Myofascial Pain

NCT05860205
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Multiple Component Mobile-Aid Pain Reduction Intervention, Osteopathic Manipulation Treatment, Sham Osteopathic Manipulation
Behavioral · Other
Lead sponsor
Kailea Manning
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Nov 2, 2026, 7:09 PM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

NCT00445705
View directory record Official record
Conditions
Fibromyalgia
Interventions
placebo, AGN 203818
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 1Phase 2 Interventional Results available

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Months to 24 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 1Phase 2 Interventional

Behavioral Insomnia Therapy With Chronic Fatigue Syndrome

NCT00540254
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Behavioral Therapy Targeted to Sleep Problems
Interventions
Cognitive Behavioral Therapy, Usual Care for Chronic Fatigue Syndrome (Active Control Group)
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Nov 2, 2026, 7:09 PM EST
Recruiting Not applicable Interventional

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

NCT06115486
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Female
Interventions
Control Arm ACSM Guidelines, Experimental Arm 6-12-25 repetitions per set
Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
20 Years to 89 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 2, 2026, 7:09 PM EST
Completed Not applicable Interventional Results available

Power Training Combined With Interval Treadmill Training

NCT03625570
View directory record Official record
Conditions
Cerebral Palsy, Central Nervous System Diseases, Brain Damage, Chronic
Interventions
Power training combined with interval treadmill training, Strength training combined with traditional treadmill training
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
10 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
New Orleans, Louisiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 2, 2026, 7:09 PM EST
Terminated Not applicable Interventional

Treating Depression in Patients With De Quervain's Tenosynovitis; An Integrated Web Based Skills Intervention

NCT04069741
View directory record Official record
Conditions
De Quervain Disease
Interventions
Decision Aid, Toolkit for de Quervain's
Other · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 3 Interventional

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

NCT00488839
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg, Placebo Baclofen Tablet, IPX056 10 mg, IPX056 30 mg, IPX056 35 mg, Placebo IPX056 20 mg, Placebo IPX056 40 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

NCT00957801
View directory record Official record
Conditions
Sarcopenia
Interventions
Testosterone injection, Testosterone gel, Medrol
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

NCT01125800
View directory record Official record
Conditions
Medulloblastoma, Rhabdomyosarcoma, Neuroblastoma, Hepatoblastoma, Glioma, Astrocytoma
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 18 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Nov 2, 2026, 7:09 PM EST
Not listed Not applicable Interventional

Inspiratory Muscle Training in COPD

NCT03438019
View directory record Official record
Conditions
COPD
Interventions
PrO2, Threshold Inspiratory Muscle Trainer
Device
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

PDE Inhibitors in DMD Study (Acute Dosing Study)

NCT01580501
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Tadalafil and Sildenafil
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
7 Years to 15 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Nov 2, 2026, 7:09 PM EST
Completed Not applicable Interventional

Sleep Intervention in Young Boys with Duchenne Muscular Dystrophy

NCT04529707
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Transdiagnostic Behavioral Sleep Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 1 Interventional

Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery

NCT00450736
View directory record Official record
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
celecoxib, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Nov 2, 2026, 7:09 PM EST
Terminated Phase 2 Interventional

An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

NCT06961344
View directory record Official record
Conditions
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mg
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 2, 2026, 7:09 PM EST
Terminated Phase 2 Interventional

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

NCT05039515
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
IPN60130, Placebo
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
5 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 2, 2026, 7:09 PM EST
Recruiting Phase 1Phase 2 Interventional

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 2, 2026, 7:09 PM EST
Completed Phase 2 Interventional Results available

Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain

NCT00524420
View directory record Official record
Conditions
Fibromyalgia, Chronic Pain, Depression
Interventions
rTMS, Sham rTMS
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Nov 2, 2026, 7:09 PM EST